January 3, 2018 / 11:12 AM / 10 months ago

BRIEF-Corsair Pharma And United Therapeutics Enter Into Strategic Collaboration To Advance Novel Treprostinil Prodrugs

Jan 3 (Reuters) - United Therapeutics Corp:

* CORSAIR PHARMA AND UNITED THERAPEUTICS ENTER INTO STRATEGIC COLLABORATION TO ADVANCE NOVEL TREPROSTINIL PRODRUGS

* UNITED THERAPEUTICS SAYS GRANTED EXCLUSIVE LICENSE TO CORSAIR’S INTELLECTUAL PROPERTY FOR DEVELOPMENT OF TREPROSTINIL PRODRUG FORMULATIONS

* UNITED THERAPEUTICS CORP - MADE MINORITY EQUITY INVESTMENT IN CORSAIR THAT INCLUDES AN OPTION TO ACQUIRE REMAINING OUTSTANDING SHARES OF CORSAIR

* UNITED THERAPEUTICS SAYS UNDER TERMS OF LICENSE AGREEMENT, CORSAIR RECEIVED UPFRONT CONSIDERATION

* UNITED THERAPEUTICS- CORSAIR IS ENTITLED TO ROYALTY PAYMENTS ON COMMERCIALIZATION OF TREPROSTINIL PRODRUG PRODUCTS BY CO COVERED BY CORSAIR’S PATENTS Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below